APA

Schmitz E. M. H., Boekema P. J., Straathof J. W. A., van Renswouw D. C., Brunsveld L., Scharnhorst V., van de Poll M. E. C., Broeren M. A. C. & Derijks L. J. J. (20190312). Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. : Alimentary pharmacology & therapeutics.

Chicago

Schmitz E M H, Boekema P J, Straathof J W A, van Renswouw D C, Brunsveld L, Scharnhorst V, van de Poll M E C, Broeren M A C and Derijks L J J. 20190312. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. : Alimentary pharmacology & therapeutics.

Harvard

Schmitz E. M. H., Boekema P. J., Straathof J. W. A., van Renswouw D. C., Brunsveld L., Scharnhorst V., van de Poll M. E. C., Broeren M. A. C. and Derijks L. J. J. (20190312). Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. : Alimentary pharmacology & therapeutics.

MLA

Schmitz E M H, Boekema P J, Straathof J W A, van Renswouw D C, Brunsveld L, Scharnhorst V, van de Poll M E C, Broeren M A C and Derijks L J J. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. : Alimentary pharmacology & therapeutics. 20190312.